Rights issue 2026

Following the promising results from the LIB-01 phase 2a study in the fall of 2025, Dicot Pharma has focused on preparations for the subsequent phase 2b study, which is planned to be conducted in the United States and Europe.

To finance the study, which is scheduled to begin in the second half of 2026, the Dicot Pharma Board of Directors intends to decide regarding a preferential issue of units of approximately SEK 210 million. The decision regarding the issue is expected to be made around May 8, 2026, based on the authorization proposed to the Annual General Meeting on May 6, 2026.

The issue is secured to 80%, corresponding to SEK 168 million, by present and new strategic investors. Besides subscription commitments and underwriting from current shareholders, underwriting has been made by Schonfeld Global Master Fund LP, Anavio Capital Partners LLP, and Vator Securities.

The Board has determined that a preferential issue that gives priority to existing shareholders while also allowing external investors to participate through underwriting commitments is preferable from a shareholder perspective and will further increase the value ahead of the anticipated outlicensing and partnerships.

This page will be updated on an ongoing basis regarding the preferential issue.